New muscle relaxant HRS-9190 tested in first human study
NCT ID NCT07142850
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and effects of a new drug called HRS-9190, designed to relax skeletal muscles. 49 healthy adults received either a single dose or a continuous infusion of the drug, sometimes with other medications. Researchers monitored side effects and how the drug moved through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-9190
What this could lead to
If successful, this could lead to a new muscle relaxant option for use during surgeries or procedures.
What could go wrong
This is an early Phase 1 study in only 49 healthy people, so it's too soon to know if it works or is safe for patients. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKELETAL MUSCLE RELAXATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, 410013, China